Although the median value in the benign group was similar to that in the control group, the elevated level in the malignant group suggested that MRP8/14 may serve as a useful biomarker for distinguishing malignant from nonmalignant ovarian disease. This evidence concerns the gene S100A8 and ovarian disorder.